Integrated Biopharma's total inventories for the quarter that ended in Mar. 2024 was $11.17 Mil. Integrated Biopharma's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $11.66 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Integrated Biopharma's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $0.10.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Integrated Biopharma's Days Inventory for the
three
months ended in Mar. 2024 was 89.41.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Integrated Biopharma's Inventory Turnover for the quarter that ended in Mar. 2024 was 1.02.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Integrated Biopharma's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.89.
Integrated Biopharma Total Inventories Historical Data
The historical data trend for Integrated Biopharma's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Biopharma Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Integrated Biopharma (OTCPK:INBP) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Integrated Biopharma's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Integrated Biopharma's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Integrated Biopharma Total Inventories Related Terms
Thank you for viewing the detailed overview of Integrated Biopharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Integrated Biopharma (Integrated Biopharma) Business Description
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. It serves the needs of the nutraceutical industry by directly doing business as Chem International Inc. and through its operating subsidiaries; Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc. and MDC Warehousing and Distribution, Inc. The company generates maximum revenue from the Contract Manufacturing segment. The business operates and generates the majority of revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INBP has been successfully added to your 